SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as the community anticipates a potential ETF and discusses market cap growth. Conversations also mention a possible breakout through the .30 mark, with some traders eyeing a move towards $1.00. The broader crypto market's potential for a strong fourth quarter is also fueling bullish sentiment.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

$BROKE.X is trending due to community excitement around an upcoming giveaway at 3.5 million MC and anticipation of the BiFinance listing. The community highlights the project's strong foundation, utility, and consistent growth within the altcoin space. Many community members express bullish sentiment and a long term investment strategy.

Ainalyzr is a versatile and engaging platform designed to provide crypto traders with advanced tools and a fun, interactive environment. Powered by the Ainalyzr token, it offers real-time analysis of Solana-based tokens, gamified trading tools, and a space for users to explore market trends and make data-driven decisions. Ainalyzr merges functionality and entertainment, appealing to both seasoned and novice traders.

AInalyzr

AInalyzr ($AINAL.X) is gaining attention, with community members highlighting its potential for a breakout and comparing it to early investments in established cryptocurrencies. Talk centers on the token's chart patterns, suggesting a possible surge, and the opportunity for early investors to benefit. The crypto is being touted as the next big play, urging others to stack now before it takes off.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as community members highlight activity around $AINAL.X, with many claiming it is poised for a breakout and urging others to get in early. Bullish sentiment also surrounds potential ETF listings and institutional investment, with some anticipating a significant price increase for SOL.X.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending as the crypto community anticipates potential market movements influenced by the upcoming Fed announcement, with some predicting significant volatility. Community members are closely watching for breakout patterns, with much of the conversation centered around a potential surge related to $AINAL.X. The broader discussion includes speculation on rate cuts and their impact on Bitcoin's price.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP.X is trending as the community anticipates potential rallies, fueled by discussions around regulatory clarity and upcoming ETF possibilities. Community members are actively debating entry points and consolidation ranges, with some eyeing October as a potentially significant month. Bullish sentiment appears to be growing, with many expressing long-term investment strategies.

$JINGLE  is a meme community on Solana, The project was fair-launched on Pump.fun, This is a purely community-driven project.  $JINGLE a community powered token celebrating global holidays!  With a dedicated team and a vibrant community, $JINGLE Token aims to bring joy and prosperity to holders while embodying the spirit of the internet's favorite amphibian. Jump on board and let's make waves in the crypto pond together!

Jingle

$JINGLE.X is trending as the community rallies around a potential pump, urging each other to buy and hold. Talk centers on anticipating a significant move, with many suggesting it's currently undervalued and coiling for a breakout. The community is drawing comparisons to other coins and emphasizing potential gains for early investors.

Voxies is a free-to-play, 3D turn-based tactical RPG game on blockchain. The main gameplay of Voxies is similar to a traditional RPG and tactical game, but it is powered by blockchain technology and ownership is central to the core concepts of the game. As a team-based tactical game, players can control multiple characters in the game and each character can be represented by Voxies that are directly owned as NFTs, or provided by the game for free-to-play players.  VOXEL is Voxies' native utility token and will be used as the currency inside the Voxie Tactics game and will be utilized for all in-game functionality, such as purchasing new weapons, armor or items to use in the game. VOXEL tokens can also be earned by playing the game and doing certain tasks — for example after each battle you will be rewarded with VOXEL tokens (and potentially rarer NFT item rewards!) depending on the success of the battle. Exploration mode will also present ways to ‘find’ and collect VOXEL token, helping out NPCs in the world and completing quests for them is another way to potentially earn rewards and VOXEL tokens.

Voxies

VOXEL.X is trending as the community discusses its potential for a significant price movement, pointing to its recent release on app stores and high trading volume. Some traders are comparing it to similar coins like LOKA.X, anticipating a breakout, while others are wary of potential pump and dump schemes.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is trending with community members actively discussing potential pumps and comparing it to other meme coins like Doge and Bonk. Some traders are debating the merits of holding SHIB, while others express excitement about its potential. There is also chatter about the broader meme coin season and potential catalysts for SHIB.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media is trending amidst politically charged discussions following news of a shooting involving figures with alleged ties to right-wing extremism, sparking heated debate and accusations. The community is actively debating the shooter's motivations, political affiliations, and the broader implications for political violence and rhetoric. Broader conversations touch upon themes of cult-like behavior, media influence, and social divisions.

statis crypto Watchlist

Ethereum

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Candel Therapeutics (CADL) Upgraded to Strong Buy: Here's What You Should Know

Candel Therapeutics (CADL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Does Candel Therapeutics (CADL) Have the Potential to Rally 285.32% as Wall Street Analysts Expect?

CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer

Shares of Candel Therapeutics, Inc. (CADL) traded 8% higher on Wednesday morning after the U.S. Food and Drug Administration (FDA) <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-receives-fda-regenerative-medicine-advanced">granted</a> Regenerative Medicine Advanced Therapy (RMAT) designation to its lead immunotherapy candidate CAN-2409 for the treatment of a certain kind of prostate cancer.CAN-2409 is being studied for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease and was previously granted FDA Fast Track designation for the same indication.RMAT designations are intended to expedite the development and review of regenerative medicine therapies intended to treat, modify, reverse, or cure serious or life-threatening diseases where preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such disease or condition.Candel’s lead candidate was granted the designation based on positive data from a late-stage trial evaluating the efficacy and safety of the investigational drug plus a prodrug, together with external beam radiation therapy, in newly diagnosed, localized, intermediate-to-high-risk prostate cancer.Candel CEO Paul Peter Tak said that the company looks forward to collaborating with the FDA on an expedited approval for the immunotherapy candidate once it submits its Biologics License Application (BLA) seeking permission to commercialize. The company is looking to submit the application by the end of 2026.RMAT designations offer the company access to mechanisms designed to fast-track BLA review and approval.CAN-2409 is also being studied for the treatment of pancreatic cancer and non-small cell lung cancer.On Stocktwits, retail sentiment around Candel jumped from ‘bullish’ to ‘extremely bullish’ over the past 24 hours while message volume jumped from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:628/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_28_at_10_27_02_AM_png_786b86992f.webp" alt="CADL's Sentiment Meter and Message Volume as of 10:25 a.m. ET on May 28, 2025 | Source: Stocktwits " width="628" height="63"><figcaption>CADL's Sentiment Meter and Message Volume as of 10:25 a.m. ET on May 28, 2025 | Source: Stocktwits&nbsp;</figcaption></figure>A Stocktwits user opined that the shares are suitable for holding in the mid- to long-term.<stembedurl>https://stocktwits.com/Bowlofpasta/message/616040223</stembedurl>According to data from Koyfin, all three analysts covering CADL rate it a ‘Buy.’ The stock has an average price target of $21.67, implying an upside of over 200% from its current value.<a href="https://stocktwits.com/symbol/CADL">CADL stock</a> is down by about 33% this year and by about 30% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/macys-q1-earnings-tops-estimates/ch0okCjRbsh">Macy’s Q1 Earnings Top Estimates, But Company Cuts 2025 Guidance Over Tariff Concerns, Weaker Consumer Sentiment</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Candel Therapeutics Stock Soars On FDA’s RMAT Designation For Prostate Cancer Therapy: Retail Considers It Good Long-Term Buy

Candel CEO Paul Peter Tak said that the company looks forward to collaborating with the FDA on an expedited approval for the immunotherapy candidate once it submits its Biologics License Application.

Candel Therapeutics Stock Soars On FDA’s RMAT Designation For Prostate Cancer Therapy

Equity

Best Momentum Stocks to Buy for May 19th

Wall Street Analysts Predict a 310.96% Upside in Candel Therapeutics (CADL): Here's  What You Should Know

Shares of Candel Therapeutics, Inc. (CADL) surged nearly 10% on Tuesday afternoon after the company reported upbeat first-quarter (Q1) earnings.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-reports-first-quarter-2025-financial-results">reported</a> diluted net income per share of $0.13 for the three months through the end of March, compared to a loss of $0.28 in the corresponding period of 2024, and surpassing an estimated loss of $0.35 per share, as per Finchat data.It said the rise in net income was primarily related to the change in the fair value of the company’s warrant liability.While research and development expenses narrowed year-on-year in the quarter, general and administrative expenses rose.The biopharmaceutical company ended the first quarter with cash and cash equivalents of $92.2 million compared to $102.7 million as of Dec. 31, 2024. Candel expects that its existing cash and cash equivalents will be sufficient to fund its current operating plan into the first quarter of 2027.CEO Paul-Peter Tak said that the company’s primary focus for 2025 remains working toward submitting an application to the U.S. Food and Drug Administration (FDA) for the commercialisation of its investigational immunotherapy candidate and lead asset CAN-2409 for the treatment of prostate cancer. The submission is expected in the fourth quarter of 2026.“We are now focusing on executing strategic preparations for potential commercialization, to ensure that, if approved, CAN-2409 is immediately available to patients with localized prostate cancer,” he said.CAN-2409 is also being studied for the treatment of pancreatic cancer and non-small cell lung cancer.On Stocktwits, retail sentiment around Candel rose within the ‘bullish’ territory over the past 24 hours while message volume jumped from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:628/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_13_at_1_41_07_PM_png_6a3877db5b.webp" alt="CADL's Sentiment Meter and Message Volume as of 1:40 p.m. ET on May 13, 2025 | Source: Stocktwits" width="628" height="62"><figcaption>CADL's Sentiment Meter and Message Volume as of 1:40 p.m. ET on May 13, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/CADL/sentiment">CADL stock</a> is down by about 39% this year and 46% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/amd-google-uber-stocks-rally-after-committing-to-invest-80-b-in-600b-us-saudi-deal/chi8AJjRbZN">AMD, Google, Uber Stocks Rally After Committing To Invest $80B As Part Of US-Saudi $600B Trade Pact</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Candel Therapeutics Stock Jumps On Upbeat Q1 Earnings: Retail Gets More Bullish

The company reported diluted net income per share of $0.13 for the three months through the end of March, compared to a loss of $0.28 in the corresponding period of 2024.

Candel Therapeutics Inc. stock ended Wednesday deep in the red but rose 1.3% in extended trading after the company announced encouraging data from a cancer drug trial.The company reported final survival data from a Phase 2a trial of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cadl-stock-jumps-on-canaccord-buy-rating/ch5uUlPRwp">CAN-2409</a> in advanced lung cancer patients who did not respond well to immune checkpoint inhibitors (ICI).&nbsp;The median overall survival (mOS) was 24.5 months for those receiving two courses of CAN-2409, significantly higher than the 9.8-11.8 months seen in similar patients receiving standard chemotherapy.The study included 46 fully treated patients, with 37% of those with progressive disease still alive after two years.&nbsp;Patients with non-squamous non-small cell lung cancer (NSCLC) showed the most potent response, with a mOS of 25.4 months in this group. Biomarker analysis indicated a stronger immune response in these patients than in those with squamous NSCLC.The treatment also appeared to induce a systemic immune response, as 69% of patients with multiple tumors saw reductions in untreated lesions.&nbsp;CAN-2409 maintained a favorable safety profile throughout the extended follow-up period, the company added.The news sent message volume about Candel on Stocktwits soaring by over 120%, with sentiment climbing further within the ‘neutral’ territory (53/100) from a day ago.<figure class="image"><img style="aspect-ratio:1318/302;" src="https://news.stocktwits-cdn.com/CADL_sentiment_and_message_volume_as_of_Macrh_26_png_1c49d17460.webp" alt="CADL sentiment and message volume as of Macrh 26.png" width="1318" height="302"><figcaption>CADL sentiment and message volume as of Macrh 26. | source: Stocktwits</figcaption></figure>One optimistic user said CAN-2409 "is worth billions," adding that Candel also had successful phase-3 trials in prostate cancer and a successful phase-2 in pancreatic cancer.<stembedurl>https://stocktwits.com/strategicmind/message/609387743</stembedurl>Another compared Candel to small-cap biotech firms that were acquired by established pharma giants such as Gilead and Pfizer for tens of billions of dollars, saying the company “will join this GOAT rodeo in no time.”<stembedurl>https://stocktwits.com/chrundel/message/609386559</stembedurl>“I could see this becoming [the] standard of care for adenocarcinoma of the lung,” said another user based on the data.<stembedurl>https://stocktwits.com/Uromaster/message/609354605</stembedurl>Last month, Candel shared updated survival data from Phase 2a trials of CAN-2409 in pancreatic cancer.&nbsp;Meanwhile, Phase 1b survival data for CAN-3110 in recurrent high-grade glioma is expected in the fourth quarter of 2025, and the company plans to submit a Biologics License Application (BLA) for CAN-2409 in prostate cancer in Q4 2026.Candel stock is down about 12% this year but has gained more than 390% in the past 12 months.&nbsp;According to Koyfin, three out of four analysts covering Candel rate it ‘buy’ while one recommends a ‘strong buy.’For updates and corrections, email newsroom[at]stocktwits[dot]com.

Illustration showing chimeric antigen receptor (CAR) T cells (blue and green) being used to treat non-small cell lung cancer (NSCLC). | Representative image: Getty Images

Candel’s Final Survival Data From Lung Cancer Drug Trial Lifts Stock After-Hours, Fuels Retail Optimism

The study included 46 fully treated patients, with 37% of those with progressive disease still alive after two years. 

Candel Therapeutics Inc. (13% jump in followers)Candel Therapeutics Inc. shares gained momentum as Wall Street analysts&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cadl-stock-jumps-on-canaccord-buy-rating/ch5uUlPRwp">highlighted</a> the potential of its lead cancer drug candidate, CAN-2409. Canaccord expects continued clinical success in prostate, pancreatic, and non-small cell lung cancer, noting a significant increase in median overall survival in testing so far. Citi’s modeling suggests CAN-2409 could extend survival in localized prostate cancer by as much as eight to nine years over radiotherapy alone.&nbsp;The stock is up over 35% year-to-date.Acelyrin Inc. (12% jump in followers)Acelyrin confirmed that Concentra Biosciences, controlled by Tang Capital Partners, submitted an unsolicited offer to acquire all outstanding shares of Acelyrin for $3.00 per share in cash, plus a contingent value right tied to future licensing or asset sales.Earlier in the month, Acelyrin announced a merger agreement with Alumis in an all-stock transaction expected to close in the second quarter of 2025, pending shareholder approval.&nbsp;Acelyrin stock is down over 18% year-to-date.Solid Biosciences Inc. (11% jump in followers)Solid Biosciences shares surged after early-stage data from its gene therapy candidate SGT-003 for Duchenne muscular dystrophy&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sldb-stock-soars-on-dmd-trial-data/ch5rNeJRvt">showed</a> promising results.&nbsp;Following the data release, Chardan raised its price target on the stock and increased the therapy’s probability of success to 48%, citing strong early efficacy signals and manageable safety risks.Solid Biosciences stock is up 43% year-to-date.Estrella Immunopharma Inc. (11% jump in followers)Estrella Immunopharma received a bullish initiation from D. Boral Capital, which started coverage with a ‘Buy’ rating and a $16 price target. The firm sees Estrella as a potential major player in immuno-oncology, with its EB103 therapy using ARTEMIS T-cell engineering technology to target solid tumors.&nbsp;The company also completed the first dose cohort in its Phase I/II trial, receiving approval from the Data and Safety Monitoring Board to proceed to the second dose level.&nbsp;Estrella stock is up over 22% year-to-date.Aditxt Inc. (10% jump in followers)Aditxt announced that its subsidiary, Pearsanta, has engaged Dominari Securities as the lead underwriter for its planned initial public offering. The IPO aims to support Pearsanta’s U.S. and international commercial launch of its Mitomic Technology platform for early cancer detection.&nbsp;Pearsanta is developing a non-invasive blood test to detect cancer at earlier stages by leveraging mitochondrial DNA deletions as biomarkers. IPO proceeds will fund the U.S. launch of its Laboratory Developed Tests (LDTs) and drive global commercialization through distribution partnerships and regulatory approvals.&nbsp;Aditxt stock is down over 53% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week

Investors on Stocktwits flocked to these five biotech stocks last week, ending Feb. 21, 2025, driven by buyout buzz, bullish analyst calls, and promising clinical developments.

Shares of Candel Therapeutics Inc. surged nearly 10% on Wednesday and extended gains in after-hours trading following a bullish call from Wall Street.Canaccord initiated coverage on the stock with a ‘Buy’ rating and a $20 price target, implying a 91% upside from the last close.&nbsp;The research firm expects continued clinical success for Candel’s lead asset, CAN-2409, in prostate, pancreatic, and non-small cell lung cancer.&nbsp;In testing so far, CAN-2409 has shown a significant increase in median overall survival. If this trend continues, it could become a “best-in-class therapy” for borderline resectable pancreatic ductal adenocarcinoma, according to the analyst.&nbsp;On Stocktwits, sentiment turned ‘extremely bullish’ on Wednesday as message volume jumped by 50% and new followers increased by 4%.&nbsp;<figure class="image"><img style="aspect-ratio:1316/316;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/CADL_sentiment_and_message_volume_Feb_19_d3c9416772.png" alt="CADL sentiment and message volume Feb 19.png" width="1316" height="316"><figcaption>CADL sentiment and message volume Feb 19 | source: Stocktwits</figcaption></figure>Traders speculated that upcoming data could drive a major rally, with some predicting that strong results from the pancreatic study could push shares into the $30-$40 range.<stembedurl>https://stocktwits.com/Xanderzzzzzzz/message/604910450</stembedurl><stembedurl>https://stocktwits.com/drizz/message/604899234</stembedurl>Last week, BofA Securities also&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cadl-stock-surges-on-bofa-buy-call/chPzAKRRtG">initiated</a> coverage on Candel with a ‘Buy’ rating and a $15 price target, citing promising early data for CAN-2409 and CAN-3110 as key drivers of its bullish outlook.&nbsp;The research firm noted that CAN-2409’s early results in prostate cancer suggest a potential breakthrough, while CAN-3110 has shown signs of nearly doubling overall survival in patients with recurrent high-grade glioma.Candel has outlined several key milestones ahead.&nbsp;Updated overall survival data from Phase 2a trials of CAN-2409 in pancreatic and non-small cell lung cancer is expected in the first quarter of 2025.&nbsp;Phase 1b survival data for CAN-3110 in recurrent high-grade glioma is set for the fourth quarter of 2025, while a Biologics License Application (BLA) submission for CAN-2409 in prostate cancer is targeted for the fourth quarter of 2026.<a href="https://stocktwits.com/symbol/CADL">Candel stock</a> is up more than 22% this year. Short interest was 6.2% as of last week, down from 14.1% at the start of the year, per Koyfin data.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Candel Therapeutics Stock Rallies On Canaccord’s Vote Of Confidence In Lead Cancer Drug: Retail Traders Rejoice

CAN-2409 could become a “best-in-class therapy” for borderline resectable pancreatic ductal adenocarcinoma, according to the analyst. 

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

CADL
Candel Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CADL News

CADL Candel Therapeutics Inc